CTY.US City Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
18.10 USD
Close of Nov 14, 2026
15.81 23.88
Market cap
USD 911M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is CTY.US undervalued?

Graham number

The Graham number of City Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

City Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for City Therapeutics, Inc. Common Stock yet.

City Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About City Therapeutics, Inc. Common Stock

City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy. It designs and engineers RNAi trigger mol…

Full company profile